Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 14;9(3):2045894019877157.
doi: 10.1177/2045894019877157. eCollection 2019 Jul-Sep.

Epidemiology and initial management of pulmonary arterial hypertension: real-world data from the Hellenic pulmOnary hyPertension rEgistry (HOPE)

Alexandra Arvanitaki  1 , Maria Boutsikou  2 , Anastasia Anthi  3 , Sotiria Apostolopoulou  4 , Aikaterini Avgeropoulou  5 , Eftychia Demerouti  4 , Dimitrios Farmakis  1 , Christos Feloukidis  1 , George Giannakoulas  1 , Haralambos Karvounis  1 , Panagiotis Karyofyllis  4 , Ioanna Mitrouska  6 , Sophia Mouratoglou  1 , Katerina K Naka  7 , Stylianos E Orfanos  3 , Evangelia Panagiotidou  8 , Georgia Pitsiou  8 , Spyridon Rammos  4 , Eleni Stagaki  3 , Ioannis Stanopoulos  8 , Adina Thomaidi  9 , Helen Triantafyllidi  3 , Iraklis Tsangaris  3 , Dimitrios Tsiapras  4 , Vassilios Voudris  4 , Athanasios Manginas  2 ; Hellenic Society for the Study of Pulmonary Hypertension (HSSPH)
Affiliations

Epidemiology and initial management of pulmonary arterial hypertension: real-world data from the Hellenic pulmOnary hyPertension rEgistry (HOPE)

Alexandra Arvanitaki et al. Pulm Circ. .

Abstract

Pulmonary arterial hypertension (PAH) is a heterogenous clinical entity with poor prognosis, despite recent major pharmacological advances. To increase awareness about the pathophysiology, epidemiology, and management of the disease, large national registries are required. The Hellenic pulmOnary hyPertension rEgistry (HOPE) was launched in early 2015 and enrolls patients from all pulmonary hypertension subgroups in Greece. Baseline epidemiologic, diagnostic, and initial treatment data of consecutive patients with PAH are presented in this article. In total, 231 patients with PAH were enrolled from January 2015 until April 2018. At baseline, about half of patients with PAH were in World Health Organization functional class II. The majority of patients with PAH (56.7%) were at intermediate 1-year mortality risk, while more than one-third were low-risk patients, according to an abbreviated risk stratification score. Half of patients with PAH were on monotherapy, 38.9% received combination therapy, while prostanoids were used only in 12.1% of patients. In conclusion, baseline data of the Greek PAH population share common characteristics, but also have some differences with other registries, the most prominent being a better functional capacity. This may reflect earlier diagnosis of PAH that in conjunction with the increased proportion of patients with atypical PAH could partially explain the preference for monotherapy and the limited use of prostanoids in Greece. Nevertheless, early, advanced specific therapy is strongly recommended.

Keywords: clinical characteristics; pulmonary arterial hypertension; risk stratification; specific medical treatment.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Classification of patients with PAH. The distribution of 231 patients across the various types of PAH in Greece (absolute number; %) is shown. HOPE: Hellenic pulmOnary hyPertension rEgistry; PAH: pulmonary arterial hypertension.
See this image and copyright information in PMC

References

    1. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46(4): 903–975. - PubMed
    1. Dodson MW, Brown LM and Elliott CG. Pulmonary arterial hypertension. Heart Fail Clin 2018; 14(3): 255–269. - PubMed
    1. McLaughlin VV, Shah SJ, Souza R, et al. Management of pulmonary arterial hypertension. J Am Coll Cardiol 2015; 65(18): 1976–1997. - PubMed
    1. Humbert M, Guignabert C, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: State of the art and research perspectives. Eur Respir J 2019; 53(1)): . - PMC - PubMed
    1. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53(1). - PMC - PubMed

LinkOut - more resources